Alluvi, initially dubbed LY3414901, represents a significant advancement in obesity management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist demonstrates remarkable efficacy in early clinical data, with substantial slimm